First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial

The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Braulke, Friederike, Zettl, Florian, Ziepert, Marita, Viardot, Andreas, Kahl, Christoph, Prange-Krex, Gabriele, Korfel, Agnieszka, Dreyling, Martin, Bott, Alexander, Wedding, Ulrich, Reichert, Dietmar, de Wit, Maike, Hartmann, Frank, Poeschel, Viola, Schmitz, Norbert, Witzens-Harig, Mathias, Klapper, Wolfram, Rosenwald, Andreas, Wulf, Gerald, Altmann, Bettina, Trümper, Lorenz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722574/
https://www.ncbi.nlm.nih.gov/pubmed/36479544
http://dx.doi.org/10.1097/HS9.0000000000000808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722574/
https://www.ncbi.nlm.nih.gov/pubmed/36479544
http://dx.doi.org/10.1097/HS9.0000000000000808

Ejemplares similares